The unprecedented scale of the COVID-19 pandemic and the rapid evolution of SARS-CoV-
2 variants underscore the need for broadly active inhibitors with a high barrier to resistance …

The SARS-CoV-2 main protease (Mpro) is a major therapeutic target. The Mpro inhibitor,
nirmatrelvir, is the antiviral component of Paxlovid, an orally available treatment for COVID …

SARS-CoV-2 continues to pose a threat to public health. Main protease (Mpro) is one of the
most lucrative drug targets for developing specific antivirals against SARS-CoV-2 infection …

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2
(SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of …

Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already
exist in clinical SARS-CoV-2 isolates. Here a robust cell-based assay is used to determine …

The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer's oral drug nirmatrelvir.
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …

Drugs that target the main protease (Mpro) of SARS-CoV-2 are effective therapeutics that
have entered clinical use. Wide-scale use of these drugs will apply selection pressure for the …

Conspectus SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …

Variants of SARS-CoV-2 have become a major public health concern due to increased
transmissibility, and escape from natural immunity, vaccine protection, and monoclonal …

The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the
spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of …